A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries
Aruni Ghose(Medway NHS Foundation Trust), Arjun K. Ghosh(University College Hospital), Sola Adeleke(King's College London), Suvro Banerjee(Apollo Hospitals), Andrés J. Daniele(Asociación por los Derechos Civiles), Ariane Vieira Scarlatelli Macedo(Santa Casa Hospital), Susan Dent(Government of the United States of America), Charlotte Manisty(National Institutes of Health), Akash Maniam(Caribbean Agricultural Research and Development Institute), Stephen Casselli, Bonnie Ky(Virginia Commonwealth University), Abhinav Kandala(University College London), Daniel J. Lenihan(Saint Francis Medical Center), Daniel Sierra-Lara Martinez(Tecnológico Nacional de México), Vanita Noronha(Homi Bhabha National Institute), Carl Simela(University College London Hospitals NHS Foundation Trust), Maryam Hasanova(University College London), Sebastian Szmit, Isha Sabnis(University of Sheffield), Mark Westwood(British Heart Foundation)
Cited by 1
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
|Circulation|2015|610
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589